Phase 3 Clinical Trials With Primary Completion Dates in October 2022

This is a list of Phase 3 trials with primary completion dates in October 2022 for companies with a market cap less than $1B. For complete clinical trial coverage, please see our Trial Tracker tool. It includes information on all clinical trials for publicly traded companies, screenable by stock symbol, market cap, disease, completion date, and phase.

The primary completion date is the date that the final subject was examined or received an intervention for the purposes of final collection of data for the primary outcome. It provides advance notice that a company will be announcing trial results in the near future.

SymbolCompanyPrimary Completion DatePhaseNCT IDTitle
ALIDAllied Corp.2022-10-01Phase 3NCT04172012Use of Probiotics to Reduce Infections, Death and ESBL Colonisation
EYPTEyePoint Pharmaceuticals, Inc.2022-10-01Phase 3NCT05070728Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert (FAI)